releases: https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=16026
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://buddycarter.house.gov/news/documentsingle.aspx?DocumentID=16026 | WATCH: Carter supports research and development to improve outcomes for children with rare diseases | 2025-12-01 | 2025 | 2025-12 | Republican | House | GA | Earl L. "Buddy" Carter | C001103 | buddycarter.house.gov | buddycarter | https://buddycarter.house.gov/news/documentquery.aspx?DocumentTypeID=27 | scraper | WASHINGTON, D.C. – Rep. Earl L. “Buddy” Carter (R-GA) today spoke on the House floor in favor of H.R. 1262, the Mikaela Naylon Give Kids a Chance Act, which boasts bipartisan support and invests in research and development of cures and treatments for children with rare diseases, including cancer. Watch and read his full speech here: “Mr. Speaker, I rise today in strong support of the bipartisan Give Kids a Chance Act, which supports research and development of drugs for children with cancer and other rare diseases. “Nearly 70% of rare diseases start in childhood, and most still have no approved treatments. The Rare Pediatric Disease Priority Review Voucher program has been a catalyst for developing therapies for these vulnerable populations. “Thanks to this program, treatments have reached children suffering from nearly 40 rare diseases, many of which previously had no FDA-approved options and often led to severe disability or death before adulthood. “Since 2012, the Rare Pediatric Disease PRV Program has helped bring more than 60 new treatments to market and has driven investment in hundreds of additional therapies for rare pediatric diseases that would otherwise be financially unviable. “The Give Kids a Chance Act restores this critical program, ensuring that we continue to spur innovation, improve outcomes for young patients, and close gaps in pediatric drug research. “Mr. Speaker, I encourage my colleagues to support this bill." | 1 | 2026-03-30T01:40:41Z | 2026-04-06T20:09:11Z |